Facilitated By

San Antonio Medical Foundation

Development of a High-Throughput Microfludics-Enabled Functional Assay for Rapidly Identifying Neutralizing Antibodies

Texas Biomedical Research Institute

 

As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.

Principal Investigator(s)
Martinez-Sobrido, Luis
Collaborating Institutions
Texas A&M University
Research Start Date
Status
Active

We will generate stocks of influenza pandemic A/California/04/09 H1N1 (pH1N1) and A/Wyoming/3/03 H3N2 influenza A viruses as well as influenza B/Brisbane/60/08 mCherry-expressing viruses that will be used to optimize the performance of PRESCIENT (Aim 1), to test the working hypothesis that PRESCIENT can identify in a mixed population of individual human hybridoma cells neutralizing antibodies against pH1N1 virus (Aim 2) and to identify influenza A H1N1, H3N2; and B virus neutralizing antibodies from EBV-immortalized patient-derived B cells (Aim 3). If needed, we will also generate stocks of the single-cycle infectious influenza pH1N1 viruses pseudotyped with the HA of influenza A pH1N1, H3N2; and B viruses (Aim 1). We will also perform traditional neutralization assays for the confirmation of the positive hits identified in the PRESCINT screening with patient-derived B cells (Aim 3).

Collaborative Project
Drug Discovery
Infectious Disease